NZ585389A - Trans-clomiphene for metabolic syndrome - Google Patents

Trans-clomiphene for metabolic syndrome

Info

Publication number
NZ585389A
NZ585389A NZ585389A NZ58538908A NZ585389A NZ 585389 A NZ585389 A NZ 585389A NZ 585389 A NZ585389 A NZ 585389A NZ 58538908 A NZ58538908 A NZ 58538908A NZ 585389 A NZ585389 A NZ 585389A
Authority
NZ
New Zealand
Prior art keywords
clomiphene
testosterone
subject
levels
serum
Prior art date
Application number
NZ585389A
Other languages
English (en)
Inventor
As Andre Van
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40023452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ585389(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of NZ585389A publication Critical patent/NZ585389A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NZ585389A 2007-10-16 2008-09-05 Trans-clomiphene for metabolic syndrome NZ585389A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98033407P 2007-10-16 2007-10-16
PCT/US2008/075433 WO2009051908A1 (en) 2007-10-16 2008-09-05 Trans-clomiphene for metabolic syndrome

Publications (1)

Publication Number Publication Date
NZ585389A true NZ585389A (en) 2011-10-28

Family

ID=40023452

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ591955A NZ591955A (en) 2007-10-16 2008-09-05 Trans-clomiphene for diabetes mellitus type 2
NZ585389A NZ585389A (en) 2007-10-16 2008-09-05 Trans-clomiphene for metabolic syndrome

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ591955A NZ591955A (en) 2007-10-16 2008-09-05 Trans-clomiphene for diabetes mellitus type 2

Country Status (24)

Country Link
US (2) US8372887B2 (OSRAM)
EP (2) EP2211848A1 (OSRAM)
JP (4) JP5558358B2 (OSRAM)
KR (1) KR101493472B1 (OSRAM)
CN (2) CN101896174B (OSRAM)
AR (1) AR069541A1 (OSRAM)
BR (1) BRPI0818637A2 (OSRAM)
CA (3) CA2806526C (OSRAM)
CL (1) CL2008002999A1 (OSRAM)
CO (1) CO6270215A2 (OSRAM)
CR (1) CR11418A (OSRAM)
EA (2) EA022760B1 (OSRAM)
EC (1) ECSP10010106A (OSRAM)
ES (1) ES2718912T3 (OSRAM)
IL (1) IL205053A (OSRAM)
ME (1) ME00996B (OSRAM)
MX (1) MX2010004195A (OSRAM)
MY (1) MY150082A (OSRAM)
NI (1) NI201000053A (OSRAM)
NZ (2) NZ591955A (OSRAM)
SG (1) SG185311A1 (OSRAM)
TW (1) TW200918093A (OSRAM)
UA (1) UA96076C2 (OSRAM)
WO (1) WO2009051908A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
CN1954807A (zh) * 2001-07-09 2007-05-02 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物
KR20070114187A (ko) 2005-03-22 2007-11-29 레프로스 쎄라피우틱스 아이엔씨. 트랜스-클로미펜의 투약 방법
NZ591955A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for diabetes mellitus type 2
TWI458478B (zh) * 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第2型糖尿病的反式氯米芬
BR112013006331B1 (pt) 2010-09-16 2021-09-21 Shimoda Biotech (Pty) Ltd Formulação compreendendo fulvestranto e ciclodextrina e seu uso
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
EP2819676B1 (en) * 2012-02-29 2018-05-30 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
CA2880388A1 (en) 2012-08-21 2014-02-27 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
WO2014070523A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
US20160051565A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor
US20160051495A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men
WO2016089904A1 (en) * 2014-12-02 2016-06-09 Repros Therapeutics Inc. Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases
EP3167870B1 (en) 2015-11-16 2024-01-03 Capsugel Belgium NV Tamperproof oral dosage form
EP3167869B1 (en) * 2015-11-16 2025-02-12 Capsugel Belgium NV Tamperproof oral dosage form
RU2611936C1 (ru) * 2016-02-16 2017-03-01 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга" Способ моделирования гипогонадизма, вызванного метаболическими нарушениями
KR20180112048A (ko) * 2016-02-25 2018-10-11 아스펜 파크 파마슈티컬스 인코포레이티드 클로미펜 이성질체들의 경구 제형 및 이차 생식선 기능저하증 치료를 위하여 이들을 사용하는 방법
WO2018027175A1 (en) * 2016-08-04 2018-02-08 University Of Iowa Research Foundation Use of swell1 inhibitors and modulators to treat type 2 diabetes and obesity

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
BE637389A (OSRAM) 1962-09-13
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
DE2658307C2 (de) 1976-12-22 1979-03-15 Klinge Pharma Gmbh & Co, 8000 Muenchen Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IE58417B1 (en) 1984-04-27 1993-09-22 Ici Plc Chemical derivatives
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3660489D1 (en) 1985-06-08 1988-09-15 Asta Pharma Ag Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US5352795A (en) 1986-03-07 1994-10-04 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE3762617D1 (de) 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8714013D0 (en) 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU665690B2 (en) 1992-05-08 1996-01-11 Otsuka Pharmaceutical Factory, Inc. Indole derivative
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
GB9326332D0 (en) 1993-12-23 1994-02-23 Karo Bio Indole derivatives
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JP2964871B2 (ja) 1994-04-20 1999-10-18 ノーリツ鋼機株式会社 ネガマスク装置
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
CA2192708A1 (en) 1994-06-17 1995-12-28 Kenneth J. Himmelstein In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
WO1997006787A2 (en) 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
CA2241623A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
BR9706966A (pt) 1996-01-11 1999-05-04 Novo Nordisk As Utilização do enanciômero-l de um composto e processo para tratamento ou profilaxia de câncer da mama
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5985910A (en) 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
JP2002511777A (ja) 1996-10-28 2002-04-16 ゼネラル ミルズ,インコーポレイテッド 調放性粒子の埋包およびカプセル化
NZ500649A (en) 1997-04-03 2001-05-25 Guilford Pharm Inc Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making a biosorbable suture, an orthopedic appliance or bone cement for repairing injuries to bone or connective tissue
ZA982818B (en) 1997-04-09 1999-10-04 Lilly Co Eli Prevention of breast cancer using selective estrogen receptor modulators.
ZA982819B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
ES2239793T3 (es) 1997-08-07 2005-10-01 Eli Lilly And Company Compuestos de 1-(4-(alcoxi sustituido)bencil)naftaleno con actividad inhibidora de estrogenos.
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
PE20000129A1 (es) 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
US6548491B2 (en) 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6069153A (en) 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
AU779398B2 (en) 1998-07-30 2005-01-20 Stoller Enterprises, Inc. Treatment of plants with salicylic acid and organic amines
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
EP1102755B1 (en) 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TR200200406T2 (tr) 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US6340774B1 (en) 2000-01-31 2002-01-22 The Board Of Trustees Of The Leland Stanford Junior University Non-steroidal estrogen-receptor antagonists
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1289519B1 (en) 2000-05-26 2019-02-13 Harry Fisch Methods of treating androgen deficiency in men using clomiphene
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001098322A1 (en) 2000-06-22 2001-12-27 Northeastern University Novel steroidal antiestrogens and antiandrogens and uses thereof
PT1318837E (pt) * 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CN1954807A (zh) 2001-07-09 2007-05-02 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
JP2005528320A (ja) 2001-08-11 2005-09-22 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 選択的なエストロゲン受容体モジュレーター
WO2003015761A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
EP1429779A2 (en) 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7138426B2 (en) 2002-04-24 2006-11-21 Merck & Co., Inc. Estrogen receptor modulators
US20080242726A1 (en) * 2004-07-14 2008-10-02 Podolski Joseph S Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
NZ556499A (en) 2005-02-04 2011-02-25 Repros Therapeutics Inc Methods and materials with trans-clomiphene for the treatment of male infertility
EP1853298A2 (en) * 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
KR20070114187A (ko) * 2005-03-22 2007-11-29 레프로스 쎄라피우틱스 아이엔씨. 트랜스-클로미펜의 투약 방법
US20080306035A1 (en) 2005-08-05 2008-12-11 Repros Therapeutics Inc. Methods and Compositions for Treating Female Infertility Using Clomiphene
EP1829534A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
NZ591955A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for diabetes mellitus type 2

Also Published As

Publication number Publication date
TW200918093A (en) 2009-05-01
CA2702710A1 (en) 2009-04-23
EP2826475B1 (en) 2019-03-20
EP2826475A1 (en) 2015-01-21
US20090099265A1 (en) 2009-04-16
CN101896174A (zh) 2010-11-24
IL205053A (en) 2014-09-30
JP2016040328A (ja) 2016-03-24
ECSP10010106A (es) 2010-06-29
EP2211848A1 (en) 2010-08-04
EA201200968A1 (ru) 2012-12-28
CA2702710C (en) 2013-05-07
CR11418A (es) 2010-08-24
AR069541A1 (es) 2010-02-03
KR101493472B1 (ko) 2015-02-16
JP5856652B2 (ja) 2016-02-10
CO6270215A2 (es) 2011-04-20
EA022760B1 (ru) 2016-02-29
CN102940619A (zh) 2013-02-27
MY150082A (en) 2013-11-29
CN101896174B (zh) 2012-10-31
BRPI0818637A2 (pt) 2015-04-07
HK1150023A1 (en) 2011-10-28
NZ591955A (en) 2011-10-28
UA96076C2 (en) 2011-09-26
CA2866905A1 (en) 2009-04-23
AU2008314538A1 (en) 2009-04-23
SG185311A1 (en) 2012-11-29
JP2017160273A (ja) 2017-09-14
CL2008002999A1 (es) 2009-03-20
US20120022167A1 (en) 2012-01-26
CA2806526C (en) 2014-12-30
IL205053A0 (en) 2010-11-30
US8372887B2 (en) 2013-02-12
JP2014185160A (ja) 2014-10-02
EA201070477A1 (ru) 2010-10-29
JP2011500690A (ja) 2011-01-06
JP5558358B2 (ja) 2014-07-23
CA2806526A1 (en) 2009-04-23
KR20100091168A (ko) 2010-08-18
US8377991B2 (en) 2013-02-19
MX2010004195A (es) 2010-06-02
EA017385B1 (ru) 2012-12-28
CA2866905C (en) 2016-04-19
WO2009051908A1 (en) 2009-04-23
NI201000053A (es) 2013-01-16
ES2718912T3 (es) 2019-07-05
ME00996B (me) 2012-10-20

Similar Documents

Publication Publication Date Title
US8372887B2 (en) Trans-clomiphene for metabolic syndrome
WO2010054248A1 (en) Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2
US9687458B2 (en) Trans-clomiphene for use in cancer therapy
CA2595363C (en) Methods and materials with trans-clomiphene for the treatment of male infertility
US20130165524A1 (en) Trans-clomiphene for metabolic syndrome
AU2008314538B2 (en) Trans-clomiphene for metabolic syndrome
HK1182618A (en) Trans-clomiphene for metabolic syndrome
HK1150023B (en) Trans-clomiphene for metabolic syndrome
US7737185B2 (en) Methods and compositions with trans-clomiphene

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2016 BY COMPUTER PACKAGES INC

Effective date: 20150818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2017 BY COMPUTER PACKAGES INC

Effective date: 20160818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2018 BY COMPUTER PACKAGES INC

Effective date: 20170818

LAPS Patent lapsed